Cargando…

Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations

SIMPLE SUMMARY: Patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene (EGFR) Exon 20 insertion mutations (Exon20ins) used to have poor outcomes after the failure of platinum-based therapies. Amivantamab, a drug that targets two proteins involved in NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Christopoulos, Petros, Girard, Nicolas, Proto, Claudia, Soares, Marta, Lopez, Pilar Garrido, van der Wekken, Anthonie J., Popat, Sanjay, Diels, Joris, Schioppa, Claudio A., Sermon, Jan, Rahhali, Nora, Pick-Lauer, Corinna, Adamczyk, Agnieszka, Penton, James, Wislez, Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670157/ https://www.ncbi.nlm.nih.gov/pubmed/38001589 http://dx.doi.org/10.3390/cancers15225326

Ejemplares similares

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
por: Chouaid, Christos, et al.
Publicado: (2023)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel, Danielle, et al.
Publicado: (2021)

Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
por: Shah, Vishal, et al.
Publicado: (2023)

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
por: Park, Keunchil, et al.
Publicado: (2021)

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
por: Petrini, Iacopo, et al.
Publicado: (2022)

The development of amivantamab for the treatment of non-small cell lung cancer
por: Brazel, Danielle, et al.
Publicado: (2023)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

Amivantamab for Metastatic Lung Cancer With Paraneoplastic Disseminated Intravascular Coagulation: A Case Report
por: Ahmad, Yaser, et al.
Publicado: (2023)

Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis
por: Van Sanden, Suzy, et al.
Publicado: (2022)

Amivantamab治疗EGFR/MET基因异常非小细胞肺癌的单中心经验
Publicado: (2022)

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
por: Cho, Byoung Chul, et al.
Publicado: (2023)

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung
por: Saffroy, Raphaël, et al.
Publicado: (2017)

Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib
por: Li, Jingjing, et al.
Publicado: (2021)

Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
por: Salles, Gilles, et al.
Publicado: (2019)

Charting the Lipopeptidome of Nonpathogenic Pseudomonas
por: Cesa-Luna, Catherine, et al.
Publicado: (2023)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
por: Chowdhury, Simon, et al.
Publicado: (2019)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

Cumulative sum charts and charting for quality improvement
por: Hawkins, Douglas M.
Publicado: (1998)

Liquid biopsies come of age in lung cancer
por: Christopoulos, Petros
Publicado: (2022)

Can we cure metastatic EGFR-mutated lung cancer today?
por: Christopoulos, Petros
Publicado: (2023)

Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer
por: Christopoulos, Petros
Publicado: (2023)

Maladie du Paget du mamelon
por: Kharmoum, Saoussane, et al.
Publicado: (2017)

Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients
por: Koele, Simon E., et al.
Publicado: (2021)

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort
por: Zou, Zihua, et al.
Publicado: (2022)

The STRAND Chart: A survival time control chart
por: Grigg, Olivia AJ
Publicado: (2018)

Chart patterns
por: Bulkowski, Thomas N
Publicado: (2014)

Growth charts
por: Khadilkar, Vaman, et al.
Publicado: (2011)

Chart of the nuclides
Publicado: (1999)

The agreement chart
por: Bangdiwala, Shrikant I, et al.
Publicado: (2013)

The Posological Chart
Publicado: (1916)

Bacteriological Chart
Publicado: (1925)

Ophthalmic Charts
Publicado: (1892)

On Temperature Charts
por: Burton-Fanning, F. W.
Publicado: (1894)

Diphtheria Chart
Publicado: (1895)

The Dispenser's Chart
Publicado: (1876)

Exhibition of Charts
Publicado: (1888)

Anatomical Charts
Publicado: (1881)

Charts and Tables
por: Ford, Richard B., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fgen1uvuf8g1osj2filoimfhlu